{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T01:43:59Z","timestamp":1792374239084,"version":"4.4.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2017,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:italic>Introduction<\/jats:italic> This was an open-label, dose escalation (3\u00a0+\u00a03 design), Phase I study of SOR-C13 in patients with advanced tumors of epithelial origin. Primary objectives were to assess safety\/tolerability and pharmacokinetics. Secondary goals were to assess pharmacodynamics and efficacy of SOR-C13. <jats:italic>Methods<\/jats:italic> SOR-C13 was administered IV QD on days 1\u20133 and 8\u201310 of a 21-day cycle. Doses were 2.75 and 5.5\u00a0mg\/kg (20-min infusion) and 1.375, 2.75, 4.13 and 6.2\u00a0mg\/kg (90-min infusion). Toxicity was assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Dose limiting toxicity (DLT) was assessed within the first treatment cycle. Tumors were evaluated, using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, after two cycles. <jats:italic>Results<\/jats:italic> Twenty-three patients were treated. No drug-related serious adverse events occurred. DLTs occurred in six patients: asymptomatic, drug-related, transient Grade 2 hypocalcemia (4 patients), and unrelated Grade 3 anemia and Grade 3 atrial fibrillation, 1 patient each. Calcium and vitamin D supplementation eliminated further Grade 2 hypocalcemia. One Grade 3 treatment emergent adverse event, urticaria, was definitely related to SOR-C13. Four possibly drug-related, Grade 3 events (alanine aminotransferase and aspartate aminotransferase elevation, headache, and hypokalemia) were observed. Of 22 evaluable patients, 54.5% showed stable disease ranging from 2.8 to 12.5\u00a0months. The best response was a 27% reduction in a pancreatic tumor with a 55% reduction in CA19\u20139 levels at 6.2\u00a0mg\/kg. <jats:italic>Conclusion<\/jats:italic> SOR-C13 was safe and tolerated up to 6.2\u00a0mg\/kg. The Maximal Tolerated Dose (MTD) was not established. Stable disease suggested antitumor activity.<\/jats:p>","DOI":"10.1007\/s10637-017-0438-z","type":"journal-article","created":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T04:45:58Z","timestamp":1485924358000},"page":"324-333","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":115,"title":["First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors"],"prefix":"10.1007","volume":"35","author":[{"given":"S.","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Hirte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Welch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. T.","family":"Ilenchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Lutes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Rice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Fields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Nemet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Dugourd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Piha-Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Subbiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,1]]},"reference":[{"issue":"3","key":"438_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058866","volume":"8","author":"CV Bowen","year":"2013","unstructured":"Bowen CV, DeBay D, Ewart HS, Gallant P, Gormley S, Ilenchuk TT, Iqbal U, Lutes T, Martina M, Mealing G, Merkley N, Sperker S, Moreno MJ, Rice C, Syvitski RT, Stewart JM (2013) In vivo detection of human TRPV6-rich tumors with anti-cancer peptides derived from soricidin. PLoS One 8(3):e58866. doi:10.1371\/journal.pone.0058866","journal-title":"PLoS One"},{"issue":"2","key":"438_CR2","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1006\/bbrc.2000.3716","volume":"278","author":"JB Peng","year":"2000","unstructured":"Peng JB, Chen XZ, Berger UV, Weremowicz S, Morton CC, Vassilev PM, Brown EM, Hediger MA (2000) Human calcium transport protein CaT1. Biochem Biophys Res Commun 278(2):326\u2013332. doi:10.1006\/bbrc.2000.3716","journal-title":"Biochem Biophys Res Commun"},{"issue":"22","key":"438_CR3","doi-asserted-by":"publisher","first-page":"19461","DOI":"10.1074\/jbc.M009895200","volume":"276","author":"U Wissenbach","year":"2001","unstructured":"Wissenbach U, Niemeyer BA, Fixemer T, Schneidewind A, Trost C, Cavalie A, Reus K, Meese E, Bonkhoff H, Flockerzi V (2001) Expression of CaT-like, a novel calcium-selective channel, correlates with the malignancy of prostate cancer. J Biol Chem 276(22):19461\u201319468. doi:10.1074\/jbc.M009895200","journal-title":"J Biol Chem"},{"issue":"49","key":"438_CR4","doi-asserted-by":"publisher","first-page":"7858","DOI":"10.1038\/sj.onc.1206895","volume":"22","author":"T Fixemer","year":"2003","unstructured":"Fixemer T, Wissenbach U, Flockerzi V, Bonkhoff H (2003) Expression of the Ca2\u00a0+\u00a0\u2212selective cation channel TRPV6 in human prostate cancer: a novel prognostic marker for tumor progression. Oncogene 22(49):7858\u20137861. doi:10.1038\/sj.onc.1206895","journal-title":"Oncogene"},{"issue":"3","key":"438_CR5","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1006\/bbrc.2001.4638","volume":"282","author":"JB Peng","year":"2001","unstructured":"Peng JB, Zhuang L, Berger UV, Adam RM, Williams BJ, Brown EM, Hediger MA, Freeman MR (2001) CaT1 expression correlates with tumor grade in prostate cancer. Biochem Biophys Res Commun 282(3):729\u2013734. doi:10.1006\/bbrc.2001.4638","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"438_CR6","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.bbrc.2004.08.042","volume":"322","author":"U Wissenbach","year":"2004","unstructured":"Wissenbach U, Niemeyer B, Himmerkus N, Fixemer T, Bonkhoff H, Flockerzi V (2004) TRPV6 and prostate cancer: cancer growth beyond the prostate correlates with increased TRPV6 Ca2+ channel expression. Biochem Biophys Res Commun 322(4):1359\u20131363. doi:10.1016\/j.bbrc.2004.08.042","journal-title":"Biochem Biophys Res Commun"},{"issue":"12","key":"438_CR7","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1097\/01.LAB.0000043910.41414.E7","volume":"82","author":"L Zhuang","year":"2002","unstructured":"Zhuang L, Peng JB, Tou L, Takanaga H, Adam RM, Hediger MA, Freeman MR (2002) Calcium-selective ion channel, CaT1, is apically localized in gastrointestinal tract epithelia and is aberrantly expressed in human malignancies. Lab Investig 82(12):1755\u20131764","journal-title":"Lab Investig"},{"issue":"2","key":"438_CR8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1158\/1535-7163.MCT-07-0478","volume":"7","author":"KA Bolanz","year":"2008","unstructured":"Bolanz KA, Hediger MA, Landowski CP (2008) The role of TRPV6 in breast carcinogenesis. Mol Cancer Ther 7(2):271\u2013279. doi:10.1158\/1535-7163.MCT-07-0478","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"438_CR9","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1158\/1535-7163.MCT-11-0965","volume":"11","author":"AA Peters","year":"2012","unstructured":"Peters AA, Simpson PT, Bassett JJ, Lee JM, Da Silva L, Reid LE, Song S, Parat MO, Lakhani SR, Kenny PA, Roberts-Thomson SJ, Monteith GR (2012) Calcium channel TRPV6 as a potential therapeutic target in estrogen receptor-negative breast cancer. Mol Cancer Ther 11(10):2158\u20132168. doi:10.1158\/1535-7163.MCT-11-0965","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"438_CR10","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1159\/000335795","volume":"28","author":"I Dhennin-Duthille","year":"2011","unstructured":"Dhennin-Duthille I, Gautier M, Faouzi M, Guilbert A, Brevet M, Vaudry D, Ahidouch A, Sevestre H, Ouadid-Ahidouch H (2011) High expression of transient receptor potential channels in human breast cancer epithelial cells and tissues: correlation with pathological parameters. Cell Physiol Biochem 28(5):813\u2013822. doi:10.1159\/000335795","journal-title":"Cell Physiol Biochem"},{"issue":"2","key":"438_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.molmed.2012.11.004","volume":"19","author":"H Ouadid-Ahidouch","year":"2013","unstructured":"Ouadid-Ahidouch H, Dhennin-Duthille I, Gautier M, Sevestre H, Ahidouch A (2013) TRP channels: diagnostic markers and therapeutic targets for breast cancer? Trends Mol Med 19(2):117\u2013124. doi:10.1016\/j.molmed.2012.11.004","journal-title":"Trends Mol Med"},{"issue":"52","key":"438_CR12","doi-asserted-by":"publisher","first-page":"7380","DOI":"10.1038\/sj.onc.1210545","volume":"26","author":"V Lehen'kyi","year":"2007","unstructured":"Lehen'kyi V, Flourakis M, Skryma R, Prevarskaya N (2007) TRPV6 channel controls prostate cancer cell proliferation via Ca(2+)\/NFAT-dependent pathways. Oncogene 26(52):7380\u20137385. doi:10.1038\/sj.onc.1210545","journal-title":"Oncogene"},{"key":"438_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.14","volume":"6","author":"CT Quang","year":"2015","unstructured":"Quang CT, Leboucher S, Passaro D, Fuhrmann L, Nourieh M, Vincent-Salomon A, Ghysdael J (2015) The calcineurin\/NFAT pathway is activated in diagnostic breast cancer cases and is essential to survival and metastasis of mammary cancer cells. Cell Death Dis 6:e1658. doi:10.1038\/cddis.2015.14","journal-title":"Cell Death Dis"},{"issue":"37","key":"438_CR14","doi-asserted-by":"publisher","first-page":"E3870","DOI":"10.1073\/pnas.1413409111","volume":"111","author":"M Raphael","year":"2014","unstructured":"Raphael M, Lehen'kyi V, Vandenberghe M, Beck B, Khalimonchyk S, Vanden Abeele F, Farsetti L, Germain E, Bokhobza A, Mihalache A, Gosset P, Romanin C, Clezardin P, Skryma R, Prevarskaya N (2014) TRPV6 calcium channel translocates to the plasma membrane via Orai1-mediated mechanism and controls cancer cell survival. Proc Natl Acad Sci U S A 111(37):E3870\u2013E3879. doi:10.1073\/pnas.1413409111","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Pt 6","key":"438_CR15","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1113\/jphysiol.2011.225862","volume":"590","author":"V Lehen'kyi","year":"2012","unstructured":"Lehen'kyi V, Raphael M, Prevarskaya N (2012) The role of the TRPV6 channel in cancer. J Physiol 590(Pt 6):1369\u20131376. doi:10.1113\/jphysiol.2011.225862","journal-title":"J Physiol"},{"issue":"3","key":"438_CR16","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1124\/pr.113.008268","volume":"66","author":"B Nilius","year":"2014","unstructured":"Nilius B, Szallasi A (2014) Transient receptor potential channels as drug targets: from the science of basic research to the art of medicine. Pharmacol Rev 66(3):676\u2013814. doi:10.1124\/pr.113.008268","journal-title":"Pharmacol Rev"},{"issue":"7608","key":"438_CR17","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nature17975","volume":"534","author":"K Saotome","year":"2016","unstructured":"Saotome K, Singh AK, Yelshanskaya MV, Sobolevsky AI (2016) Crystal structure of the epithelial calcium channel TRPV6. Nature 534(7608):506\u2013511. doi:10.1038\/nature17975","journal-title":"Nature"},{"issue":"5\u20136","key":"438_CR18","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0143-4160(03)00065-4","volume":"33","author":"E den Dekker","year":"2003","unstructured":"den Dekker E, Hoenderop JG, Nilius B, Bindels RJ (2003) The epithelial calcium channels, TRPV5 & TRPV6: from identification towards regulation. Cell Calcium 33(5\u20136):497\u2013507","journal-title":"Cell Calcium"},{"issue":"15","key":"438_CR19","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1093\/jnci\/89.15.1138","volume":"89","author":"R Simon","year":"1997","unstructured":"Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC (1997) Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89(15):1138\u20131147","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"438_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247. doi:10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"issue":"3","key":"438_CR21","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/sj.bjc.6605175","volume":"101","author":"LC Scott","year":"2009","unstructured":"Scott LC, Evans TR, Cassidy J, Harden S, Paul J, Ullah R, O'Brien V, Brown R (2009) Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response. Br J Cancer 101(3):410\u2013417. doi:10.1038\/sj.bjc.6605175","journal-title":"Br J Cancer"}],"updated-by":[{"DOI":"10.1007\/s10637-017-0455-y","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2017,4,7]],"date-time":"2017-04-07T00:00:00Z","timestamp":1491523200000}}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-017-0438-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-017-0438-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-017-0438-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T05:04:54Z","timestamp":1678511094000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-017-0438-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,1]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["438"],"URL":"https:\/\/doi.org\/10.1007\/s10637-017-0438-z","relation":{"erratum":[{"id-type":"doi","id":"10.1007\/s10637-017-0455-y","asserted-by":"object"}]},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,1]]},"assertion":[{"value":"19 December 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Soricimed Biopharma Inc. sponsored this Phase I clinical study. The only potential conflict of interest because of holding shares in the company is JMS. Research ethics boards of the participating clinical sites approved all protocols and amendments.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}